ArticleFrontiers in immunology2026
A novel
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Nutritional supplementation with ω-3 polyunsaturated fatty acids has shown potential benefits in inflammatory bowel disease, although clinical responses remain inconsistent. This may be partly due to the limited conversion of ω-3 PUFAs into specialized pro-resolving mediators under physiological conditions. Methods: We investigated whether fermentation of ω-3 PUFA lysine salt with Bacillus megaterium DSM 32963 enhanced its anti-inflammatory and pro-resolving activity. The resulting formulation was evaluated in ex vivo colon biopsies obtained from patients with ulcerative colitis (UC) and healthy subjects. Inflammatory cytokine expression and macrophage-associated markers were assessed using qPCR, Western blotting and immunofluorescence. Results: The B. megaterium/ω-3 PUFA formulation modulated the inflammatory response in ulcerative colitis biopsies, reducing the expression of selected pro-inflammatory cytokines and promoting a macrophage profile associated with resolution of inflammation. Discussion: These findings provide preliminary evidence that microbial conversion of ω-3 PUFAs can enhance their pro-resolving activity in human colonic tissue. This synbiotic approach may represent a promising nutritional adjunct for ulcerative colitis, although further in vivo and clinical investigations are required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.